+++ Trevena +++ Revolution in der Schmerztherapie? (Seite 90)
eröffnet am 04.01.18 20:37:22 von
neuester Beitrag 03.02.24 08:02:54 von
neuester Beitrag 03.02.24 08:02:54 von
Beiträge: 2.375
ID: 1.270.862
ID: 1.270.862
Aufrufe heute: 0
Gesamt: 280.106
Gesamt: 280.106
Aktive User: 0
ISIN: US89532E2081 · WKN: A3DWN1 · Symbol: 6T40
0,3705
EUR
+3,78 %
+0,0135 EUR
Letzter Kurs 25.04.24 Tradegate
Werte aus der Branche Biotechnologie
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 1,9000 | +59,66 | |
| 4,7450 | +35,57 | |
| 0,5250 | +19,08 | |
| 5,8900 | +17,80 | |
| 12,800 | +17,43 |
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 1,6900 | -14,50 | |
| 2,8150 | -15,21 | |
| 3,0400 | -19,95 | |
| 1,9500 | -25,14 | |
| 0,5121 | -30,80 |
Beitrag zu dieser Diskussion schreiben
Feedback
Antwort auf Beitrag Nr.: 63.419.201 von bcgk am 22.04.20 20:29:45
...und mit festgerosteten und blockierten Bremsen
Zitat von bcgk: Trevena ist ein Lada von 1951 ohne Räder.
...und mit festgerosteten und blockierten Bremsen
Antwort auf Beitrag Nr.: 63.418.697 von DWL33 am 22.04.20 19:53:33Trevena ist ein Lada von 1951 ohne Räder.
Antwort auf Beitrag Nr.: 63.417.827 von bcgk am 22.04.20 18:49:19Ja man wundert sich manchmal.
Ich muss das noch mal mit der aktuellen Aktienzahl durchrechnen und Trevena ist heute gefallen während Baudax zugelegt hat. Auf den ersten Blick sieht es aber so aus als würde man Mcap - Cash Baudax günstiger bekommen als Trevena. Gleiche Indikation aber Baudax hat das bessere Produkt, Zulassung schon in der Tasche und gerade erst KE gehabt. Restliche Pipeline bei Baudax ist auch schon wesentlicher weiter.
Entsprechend entwickeln sich die Kurse auch heute und voraussichtlich auch die nächsten Wochen. Im Vergleich ist das wie ein Golf ohne TÜV der durch die letzte Prüfung gefallen ist mit leerem Tank der aber teurer ist als eine C Klasse, mit TÜV neu und vollgetankt.
Ich muss das noch mal mit der aktuellen Aktienzahl durchrechnen und Trevena ist heute gefallen während Baudax zugelegt hat. Auf den ersten Blick sieht es aber so aus als würde man Mcap - Cash Baudax günstiger bekommen als Trevena. Gleiche Indikation aber Baudax hat das bessere Produkt, Zulassung schon in der Tasche und gerade erst KE gehabt. Restliche Pipeline bei Baudax ist auch schon wesentlicher weiter.
Entsprechend entwickeln sich die Kurse auch heute und voraussichtlich auch die nächsten Wochen. Im Vergleich ist das wie ein Golf ohne TÜV der durch die letzte Prüfung gefallen ist mit leerem Tank der aber teurer ist als eine C Klasse, mit TÜV neu und vollgetankt.
Antwort auf Beitrag Nr.: 63.416.945 von DWL33 am 22.04.20 17:51:33
Doch, sie meint das ernst. Sie weiß es halt nicht besser.
Zitat von DWL33: Ja, das sind ähnliche Nebenwirkungen wie bei Aspirin, auch da kann es zu Blutungen im Magen kommen und es kommt zu Blutverdünnung.
Willst Du damit jetzt argumentieren bei derart gelagerten Nebenwirkungen sollte man lieber Opioide nehmen? Das meinst Du hoffentlich nicht wirklich!.
Doch, sie meint das ernst. Sie weiß es halt nicht besser.
Trading Spotlight
Der Kurs pendelt sich wieder schön in den Abwärtskanal ein, ich denke diese Woche Testen wir nochmal die $0,60.
go short - stay positive
go short - stay positive
Als Ergebnis können wir festhalten Meloxicam hat ein deutlich besseres Nebenwirkungsprofil , muss nur einmal täglich verabreicht werden , und hat kein Suchpotential.
Es ist ok wenn Du nicht inhaltlich Diskutieren möchtest, als Vertreter von Oli würde ich das auch so gut wie möglich vermeiden wollen.
Es ist ok wenn Du nicht inhaltlich Diskutieren möchtest, als Vertreter von Oli würde ich das auch so gut wie möglich vermeiden wollen.
Als Boxed Warning ist es unwesentlich kürzer, es wird auf den Volltext verwiesen. 7. kommt dafür noch hinzu.
Quelle: siehe vorheriges Posting.
wenn man wichtig tut, sollte man wenigstens den Unterschied zwischen einer "BlackBox" und den Nebenwirkungen verstanden haben.
Aber da ist dann wieder einmal "mehr Schein als Sein".
Business as usual.
Ich habe aber heute auch gar keine Lust auf infantile Diskussionen - deswegen an alle wirklich Diskutierenden...a demain!
Aber da ist dann wieder einmal "mehr Schein als Sein".
Business as usual.
Ich habe aber heute auch gar keine Lust auf infantile Diskussionen - deswegen an alle wirklich Diskutierenden...a demain!
Vielleicht mal zum Vergleich das ganze bei Morphin, das gleiche gilt (lt. CH in abgeschwächter Form) für Oli:
5 WARNINGS AND PRECAUTIONS
5.1 Risk of Medication Errors
Morphine Sulfate Injection is available in five concentrations for direct injection. Take care when
prescribing and administering Morphine Sulfate Injection to avoid dosing errors due to confusion between
different concentrations and between mg and mL, which could result in accidental overdose and death.
Take care to ensure the proper dose is communicated and dispensed. When writing prescriptions, include
both the total dose in mg and the total dose in volume.
5.2 Cardiovascular Instability
While low doses of intravenously administered morphine have little effect on cardiovascular
stability, high doses are excitory, resulting from sympathetic hyperactivity and increase in circulatory
catecholamines. Have Naloxone Injection and resuscitative equipment immediately available for use in
case of life-threatening or intolerable side effects and whenever morphine therapy is being initiated.
5.3 Respiratory Depression
Respiratory depression is the primary risk of Morphine Sulfate Injection USP. Respiratory
depression occurs more frequently in elderly or debilitated patients and in those suffering from conditions
accompanied by hypoxia, hypercapnia, or upper airway obstruction, in whom even moderate therapeutic
doses may significantly decrease pulmonary ventilation. Morphine administration should be limited to use
by those familiar with the management of respiratory depression. Rapid intravenous administration may
result in chest wall rigidity.
Reference ID: 3043802
Patients with chronic obstructive pulmonary disease or cor pulmonale and in patients having a
substantially decreased respiratory reserve (e.g., severe kyphoscoliosis), hypoxia, hypercapnia, or
preexisting respiratory depression have an increased risk of increased airway resistance and decrease
respiratory drive to the point of apnea with use of Morphine Sulfate Injection USP. Therefore, consider
alternative non-opioid analgesics, and use Morphine Sulfate Injection USP only under careful medical
supervision at the lowest effective dose in such patients.
5.4 Central Nervous System (CNS) Toxicity
Excitation of the central nervous system, resulting in convulsion, may accompany high doses of
morphine given intravenously. Dysphoric reactions may occur after any size dose and toxic psychoses
have been reported.
5.5 Misuse, Abuse and Diversion of Opioids
Morphine sulfate is an opioid agonist and Schedule II controlled substance. Such drugs are sought
by drug abusers and people with addiction disorders. Diversion of Scheduled II products is an act subject
to criminal penalty. [See Drug Abuse and Dependence (9).]
Morphine sulfate can be abused in a manner similar to other opioid agonists, legal or illicit. This
should be considered when prescribing or dispensing Morphine Sulfate Injection USP in situations where
the physician or pharmacist is concerned about an increased risk of misuse, abuse, or diversion.
Concerns about abuse, addiction, and diversion should not prevent the proper management of
pain. Healthcare professionals should contact their State of Professional Licensing Board or State
Controlled Substances Authority for information on how to prevent and detect abuse or diversion of this
product.
5.6 Central Nervous System (CNS) Depressants
The depressant effects of morphine are potentiated by the presence of other CNS depressants such
as alcohol, sedatives, antihistamines, or psychotropic drugs. Use of Morphine in conjunction with other
CNS active drugs may increase the risk of respiratory depression, hypotension, profound sedation, coma,
or death.
5.7 Increased Intracranial Pressure or Head Injury
Use Morphine Sulfate Injection with extreme caution in patients with head injury or increased
intracranial pressure. In the presence of head injury, intracranial lesions or a preexisting increase in
intracranial pressure, the possible respiratory depressant effects of Morphine Sulfate Injection USP and its
potential to elevate cerebrospinal fluid pressure (resulting from vasodilation following CO2 retention) may
be markedly exaggerated. Pupillary changes (miosis) from morphine may obscure the existence, extent
and course of intracranial pathology. Clinicians should maintain a high index of suspicion for adverse
drug reactions when evaluating altered mental status or movement abnormalities in patients receiving this
modality of treatment.
5.8 Hypotensive Effect
Morphine Sulfate Injection may cause severe hypotension in an individual whose ability to
maintain their blood pressure has been compromised by depleted blood volume, shock, impaired
myocardial function or concurrent administration of sympatholytic drugs, and drugs such as
phenothiazines or general anesthetics. Orthostatic hypotension is a frequent complication in single-dose
parenteral morphine analgesia in ambulatory patients.
The vasodilation produced by Morphine Sulfate Injection USP may further reduce cardiac output
and blood pressure in patients in circulatory shock.
Reference ID: 3043802
5.9 Driving and Operating Machinery
Morphine may impair the mental and physical abilities needed to perform potentially hazardous
activities such as driving a car or operating machinery. Caution patients accordingly.
5.10 Gastrointestinal Effects
Do not administer Morphine Sulfate Injection USP to patients with gastrointestinal obstruction,
especially paralytic ileus because Morphine Sulfate Injection USP diminishes propulsive peristaltic waves
in the gastrointestinal tract and may prolong the obstruction.
The administration of Morphine Sulfate Injection USP may obscure the diagnosis or clinical
course in patients with acute abdominal condition.
5.11 Use in Biliary Surgery or Disorders of the Biliary Tract
Morphine Sulfate Injection USP may cause spasm of the sphincter of Oddi and diminish biliary
and pancreatic secretions.
5.12 Special Risk Groups
Use Morphine Sulfate Injection USP with caution and in reduced dosages in patients with severe
renal or hepatic impairment, Addison’s disease, hypothyroidism, prostatic hypertrophy, or urethral
stricture, and in elderly or debilitated patients. [See Use in Specific Populations (8.5).]
Exercise caution in the administration of Morphine Sulfate Injection USP to patients with CNS
depression, toxic psychosis, acute alcoholism and delirium tremens.
Q: https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/20…
5 WARNINGS AND PRECAUTIONS
5.1 Risk of Medication Errors
Morphine Sulfate Injection is available in five concentrations for direct injection. Take care when
prescribing and administering Morphine Sulfate Injection to avoid dosing errors due to confusion between
different concentrations and between mg and mL, which could result in accidental overdose and death.
Take care to ensure the proper dose is communicated and dispensed. When writing prescriptions, include
both the total dose in mg and the total dose in volume.
5.2 Cardiovascular Instability
While low doses of intravenously administered morphine have little effect on cardiovascular
stability, high doses are excitory, resulting from sympathetic hyperactivity and increase in circulatory
catecholamines. Have Naloxone Injection and resuscitative equipment immediately available for use in
case of life-threatening or intolerable side effects and whenever morphine therapy is being initiated.
5.3 Respiratory Depression
Respiratory depression is the primary risk of Morphine Sulfate Injection USP. Respiratory
depression occurs more frequently in elderly or debilitated patients and in those suffering from conditions
accompanied by hypoxia, hypercapnia, or upper airway obstruction, in whom even moderate therapeutic
doses may significantly decrease pulmonary ventilation. Morphine administration should be limited to use
by those familiar with the management of respiratory depression. Rapid intravenous administration may
result in chest wall rigidity.
Reference ID: 3043802
Patients with chronic obstructive pulmonary disease or cor pulmonale and in patients having a
substantially decreased respiratory reserve (e.g., severe kyphoscoliosis), hypoxia, hypercapnia, or
preexisting respiratory depression have an increased risk of increased airway resistance and decrease
respiratory drive to the point of apnea with use of Morphine Sulfate Injection USP. Therefore, consider
alternative non-opioid analgesics, and use Morphine Sulfate Injection USP only under careful medical
supervision at the lowest effective dose in such patients.
5.4 Central Nervous System (CNS) Toxicity
Excitation of the central nervous system, resulting in convulsion, may accompany high doses of
morphine given intravenously. Dysphoric reactions may occur after any size dose and toxic psychoses
have been reported.
5.5 Misuse, Abuse and Diversion of Opioids
Morphine sulfate is an opioid agonist and Schedule II controlled substance. Such drugs are sought
by drug abusers and people with addiction disorders. Diversion of Scheduled II products is an act subject
to criminal penalty. [See Drug Abuse and Dependence (9).]
Morphine sulfate can be abused in a manner similar to other opioid agonists, legal or illicit. This
should be considered when prescribing or dispensing Morphine Sulfate Injection USP in situations where
the physician or pharmacist is concerned about an increased risk of misuse, abuse, or diversion.
Concerns about abuse, addiction, and diversion should not prevent the proper management of
pain. Healthcare professionals should contact their State of Professional Licensing Board or State
Controlled Substances Authority for information on how to prevent and detect abuse or diversion of this
product.
5.6 Central Nervous System (CNS) Depressants
The depressant effects of morphine are potentiated by the presence of other CNS depressants such
as alcohol, sedatives, antihistamines, or psychotropic drugs. Use of Morphine in conjunction with other
CNS active drugs may increase the risk of respiratory depression, hypotension, profound sedation, coma,
or death.
5.7 Increased Intracranial Pressure or Head Injury
Use Morphine Sulfate Injection with extreme caution in patients with head injury or increased
intracranial pressure. In the presence of head injury, intracranial lesions or a preexisting increase in
intracranial pressure, the possible respiratory depressant effects of Morphine Sulfate Injection USP and its
potential to elevate cerebrospinal fluid pressure (resulting from vasodilation following CO2 retention) may
be markedly exaggerated. Pupillary changes (miosis) from morphine may obscure the existence, extent
and course of intracranial pathology. Clinicians should maintain a high index of suspicion for adverse
drug reactions when evaluating altered mental status or movement abnormalities in patients receiving this
modality of treatment.
5.8 Hypotensive Effect
Morphine Sulfate Injection may cause severe hypotension in an individual whose ability to
maintain their blood pressure has been compromised by depleted blood volume, shock, impaired
myocardial function or concurrent administration of sympatholytic drugs, and drugs such as
phenothiazines or general anesthetics. Orthostatic hypotension is a frequent complication in single-dose
parenteral morphine analgesia in ambulatory patients.
The vasodilation produced by Morphine Sulfate Injection USP may further reduce cardiac output
and blood pressure in patients in circulatory shock.
Reference ID: 3043802
5.9 Driving and Operating Machinery
Morphine may impair the mental and physical abilities needed to perform potentially hazardous
activities such as driving a car or operating machinery. Caution patients accordingly.
5.10 Gastrointestinal Effects
Do not administer Morphine Sulfate Injection USP to patients with gastrointestinal obstruction,
especially paralytic ileus because Morphine Sulfate Injection USP diminishes propulsive peristaltic waves
in the gastrointestinal tract and may prolong the obstruction.
The administration of Morphine Sulfate Injection USP may obscure the diagnosis or clinical
course in patients with acute abdominal condition.
5.11 Use in Biliary Surgery or Disorders of the Biliary Tract
Morphine Sulfate Injection USP may cause spasm of the sphincter of Oddi and diminish biliary
and pancreatic secretions.
5.12 Special Risk Groups
Use Morphine Sulfate Injection USP with caution and in reduced dosages in patients with severe
renal or hepatic impairment, Addison’s disease, hypothyroidism, prostatic hypertrophy, or urethral
stricture, and in elderly or debilitated patients. [See Use in Specific Populations (8.5).]
Exercise caution in the administration of Morphine Sulfate Injection USP to patients with CNS
depression, toxic psychosis, acute alcoholism and delirium tremens.
Q: https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/20…
Durchsuchen
